Article
Crystal structure of the T315I mutant of AbI kinase.
Chemical biology & drug design - 1 Sept 2007
Zhou Tianjun, Parillon Lois, Li Feng, Wang Yihan, Keats Jeff, Lamore Sarah, Xu Qihong, Shakespeare William, Dalgarno David, Zhu Xiaotian
Abstract excerpt
Imatinib (Gleevec) is currently the frontline therapy for chronic myeloid leukemia (CML), a disease characterized by the presence of a constitutively activated chimeric tyrosine kinase protein Bcr-AbI. However, drug resistance often occurs at later stages of the disease, principally because of the occurrence of mutations in the kinase domain. Second generation Bcr-AbI inhibitors, such as dasatinib and nilotinib...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.